{"id":22210,"date":"2023-02-06T13:23:00","date_gmt":"2023-02-06T05:23:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22210"},"modified":"2025-01-20T13:28:03","modified_gmt":"2025-01-20T05:28:03","slug":"zhimeng-biopharma-signs-global-licensing-deal-with-gsk-for-tlr8-agonist-cb06","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22210","title":{"rendered":"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06"},"content":{"rendered":"\n

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK major GlaxoSmithKline (NYSE: GSK<\/a>) focused on Zhimeng’s in-house developed toll-like receptor 8 (TLR8) agonist CB06. The agreement, with no financial details disclosed, grants GSK development, manufacturing, and commercialization rights to the drug candidate once it completes Phase I trials managed by Zhimeng Bio.<\/p>\n\n\n\n

CB06: Mechanism and Potential Uses<\/strong>
CB06 is a TLR8 agonist that has shown good selectivity, activity, and safety in preclinical studies. It can induce cytokines in human peripheral blood mononuclear cells, which activate antiviral functions through various immune mediators. CB06 also has strong liver-targeting characteristics, making it a promising candidate for hepatitis B virus (HBV) treatment. If successful, CB06 can be used in combination with other drugs or as sequential therapy combined with bepirovirsen, an antisense oligonucleotide therapy co-developed by GSK and Ionis Pharmaceutical.<\/p>\n\n\n\n

Zhimeng Bio’s Core Programs<\/strong>
Zhimeng Bio is a specialist biopharma focused on liver and central nervous system diseases. Its core anti-HBV program, nucleocapsid inhibitor ZM-H1505R, has completed Phase Ib stage studies and is entering the Phase II stage. This progress highlights Zhimeng Bio’s commitment to advancing innovative treatments for hepatitis B and other liver-related conditions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[278,914,89,1096],"class_list":["post-22210","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-glaxosmithkline","tag-nyse-gsk","tag-viral-hepatitis","tag-zhimeng-biopharma"],"yoast_head":"\nZhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK major GlaxoSmithKline (NYSE: GSK) focused on Zhimeng's in-house developed toll-like receptor 8 (TLR8) agonist CB06. The agreement, with no financial details disclosed, grants GSK development, manufacturing, and commercialization rights to the drug candidate once it completes Phase I trials managed by Zhimeng Bio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22210\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22210\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-06T05:23:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-20T05:28:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22210#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22210\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06\",\"datePublished\":\"2023-02-06T05:23:00+00:00\",\"dateModified\":\"2025-01-20T05:28:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22210\"},\"wordCount\":216,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"GlaxoSmithKline\",\"NYSE: GSK\",\"Viral hepatitis\",\"Zhimeng Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22210#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22210\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22210\",\"name\":\"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-06T05:23:00+00:00\",\"dateModified\":\"2025-01-20T05:28:03+00:00\",\"description\":\"Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK major GlaxoSmithKline (NYSE: GSK) focused on Zhimeng's in-house developed toll-like receptor 8 (TLR8) agonist CB06. The agreement, with no financial details disclosed, grants GSK development, manufacturing, and commercialization rights to the drug candidate once it completes Phase I trials managed by Zhimeng Bio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22210#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22210\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22210#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06 - Insight, China's Pharmaceutical Industry","description":"Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK major GlaxoSmithKline (NYSE: GSK) focused on Zhimeng's in-house developed toll-like receptor 8 (TLR8) agonist CB06. The agreement, with no financial details disclosed, grants GSK development, manufacturing, and commercialization rights to the drug candidate once it completes Phase I trials managed by Zhimeng Bio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22210","og_locale":"en_US","og_type":"article","og_title":"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22210","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-06T05:23:00+00:00","article_modified_time":"2025-01-20T05:28:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22210#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22210"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06","datePublished":"2023-02-06T05:23:00+00:00","dateModified":"2025-01-20T05:28:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22210"},"wordCount":216,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["GlaxoSmithKline","NYSE: GSK","Viral hepatitis","Zhimeng Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22210#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22210","url":"https:\/\/flcube.com\/?p=22210","name":"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-06T05:23:00+00:00","dateModified":"2025-01-20T05:28:03+00:00","description":"Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK major GlaxoSmithKline (NYSE: GSK) focused on Zhimeng's in-house developed toll-like receptor 8 (TLR8) agonist CB06. The agreement, with no financial details disclosed, grants GSK development, manufacturing, and commercialization rights to the drug candidate once it completes Phase I trials managed by Zhimeng Bio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22210#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22210"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22210#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22210","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22210"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22210\/revisions"}],"predecessor-version":[{"id":22212,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22210\/revisions\/22212"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22210"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22210"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22210"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}